CLVT · Clarivate PLC · Documents

$2.33 +0.21 (+9.91%) At close · Nov 5 Play latest call Q3 2026 earnings call transcript

Russell 2000 member Rebalance outlook locked

Market Cap

$1.49B

639.90M

Volume · Nov 5 7.13M Avg daily vol (3M) 4.22M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $2.46B down 4.0% 10-K filed Feb 24, 2026 Quarterly report New FY2026 Q3 Revenue $481.6M down 9.2% 10-Q filed Nov 3, 2026 Latest results New Financial results 8-K filed Nov 3, 2026 Earnings call New Q3 2026 earnings call Held Nov 3, 2026

2026

Nov 4

Current report 8-K

Debt tender offers capped at $500,000,000

Clarivate announced cash tender offers for certain debt securities, capped at $500,000,000 aggregate and scheduled to expire on November 10, 2026 unless extended.

Other events

3 source passages

On November 4, 2026, Clarivate Plc issued a press release announcing the launch of cash tender offers by its wholly-owned subsidiary, Clarivate Science Holdings Corporation, for certain of its debt securities. The Company is offering to purchase in the Offers its 3.875% Senior Secured Notes due 2028 (the “2028 Notes”) and its 4.875% Senior Notes due 2029 (the “2029 Notes” and, together with the 2028 Notes, the “Notes” and, each, a “Series of Notes”) for the applicable consideration described below, subject to a $500,000,000 cap on the aggregate principal amount of Notes purchased in the Offers (the "Tender Cap"), proration and the terms and conditions, including, among others, a $400,000,000 cap on the aggregate principal amount of the 2028 Notes to be purchased and a $100,000,000 cap on the aggregate principal amount of the 2029 Notes to be purchased pursuant to the Offers (each, a “Series Cap”) set forth in the Offer to Purchase. The Offers are scheduled to expire on the Expiration Date, which is 5:00 p.m., New York City time, on November 10, 2026, unless extended or earlier terminated by the Company with respect to any Offer. Open the document at this passage

Nov 3

Earnings call

Q3 2026 earnings call AI summary on its way

Nov 3

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Quarterly report for FY2026 Q3

Clarivate PLC completed the sale of its LS&H segment on October 6, 2026, receiving $488.4 in cash at close. Nine-month revenue was $1,472.4, down (5) %, Adjusted EBITDA was $645.6, and free cash flow was $233.1.

Revenue $481.6M ▼ 9.2% Net loss $80.8M Diluted EPS -$0.13

Read from the MD&A section

Nov 3

Current report 8-K

Financial results, Regulation FD disclosure

Clarivate reported third-quarter revenue of $481.6 million and organic revenue growth of 0.4%; net loss including LS&H was $80.8 million, or $0.13 per diluted share. It completed the LS&H divestiture for net cash proceeds of $488.4 million.

Oct 13

Current report 8-K/A Events of Oct 6

Completed an acquisition or sale of assets

Clarivate completed the sale of its Life Sciences and Healthcare business to an Altaris, LLC affiliate on October 6, 2026 for $600 million, receiving approximately $488.4 million in cash at close; the business is classified as discontinued operations.

Oct 6

Current report 8-K

Completed an acquisition or sale of assets, Director or officer change, or executive pay, Other events

Sep 24

Current report 8-K

Other events

Clarivate PLC’s wholly-owned subsidiary tender offer for 3.875% Senior Secured Notes due 2028 expired September 23, 2026; $665,198,000 was tendered, $75,000,000 accepted at an 11.3% proration factor, with settlement September 25, 2026.

Sep 23

Current report 8-K

Other events

Clarivate Plc priced a cash tender offer by Clarivate Science Holdings Corporation for 3.875% Senior Secured Notes due 2028, paying $975.15 per $1,000 principal amount, subject to a $75,000,000 cap.

Sep 17

Current report 8-K

Other events AI summary on its way

Jul 29

Current report 8-K Events of Jul 24

Director or officer change, or executive pay, Regulation FD disclosure AI summary on its way

Jul 29

Current report 8-K

Financial results, Regulation FD disclosure AI summary on its way

Jul 29

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way